Literature DB >> 28899686

The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies.

Anika Kasprick1, Maike M Holtsche2, Eileen L Rose3, Sami Hussain3, Enno Schmidt4, Frank Petersen5, Sandip Panicker3, Ralf J Ludwig4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28899686     DOI： 10.1016/j.jid.2017.08.030

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  13 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

2.  C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.

Authors:  Pavel A Nikitin; Eileen L Rose; Tony S Byun; Graham C Parry; Sandip Panicker
Journal:  J Immunol       Date:  2019-01-11       Impact factor: 5.422

Review 3.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

Review 4.  Drug Development in Pemphigoid Diseases.

Authors:  Katja Bieber; Ralf J Ludwig
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

5.  Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Unni K Samavedam; Nina Mitschker; Anika Kasprick; Katja Bieber; Enno Schmidt; Tamás Laskay; Andreas Recke; S Goletz; Gestur Vidarsson; Franziska S Schulze; Mikko Armbrust; Katharina Schulze Dieckhoff; Hendri H Pas; Marcel F Jonkman; Kathrin Kalies; Detlef Zillikens; Yask Gupta; Saleh M Ibrahim; Ralf J Ludwig
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

6.  A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.

Authors:  Johann Bartko; Christian Schoergenhofer; Michael Schwameis; Christa Firbas; Martin Beliveau; Colin Chang; Jean-Francois Marier; Darrell Nix; James C Gilbert; Sandip Panicker; Bernd Jilma
Journal:  Clin Pharmacol Ther       Date:  2018-07-13       Impact factor: 6.875

Review 7.  Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin.

Authors:  Natalie E Stevens; Allison J Cowin; Zlatko Kopecki
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

Review 8.  Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review.

Authors:  Gareth Edwards; Gilles F H Diercks; Marc A J Seelen; Barbara Horvath; Martijn B A van Doorn; Jeffrey Damman
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

9.  Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Authors:  Sidonia Mihai; Misa Hirose; Yi Wang; Joshua M Thurman; V Michael Holers; B Paul Morgan; Jörg Köhl; Detlef Zillikens; Ralf J Ludwig; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561

Review 10.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.